Publications

Detailed Information

Analysis of clinical and genomic profiles of therapy-related myeloid neoplasm in Korea

Cited 0 time in Web of Science Cited 0 time in Scopus
Authors

Yun, Jiwon; Song, Hyojin; Kim, Sung-Min; Kim, Soonok; Kwon, Seok Ryun; Lee, Young Eun; Jeong, Dajeong; Park, Jae Hyeon; Kwon, Sunghoon; Yun, Hongseok; Lee, Dong Soon

Issue Date
2023-02-23
Publisher
BMC
Citation
Human Genomics, 17(1):13
Keywords
Therapy-related myeloid neoplasmNext-generation sequencingGermline predispositionSomatic mutation
Abstract
Background
Therapy-related myeloid neoplasm (T-MN) rarely occurs among cancer survivors, and wascharacterized by poor prognosis. T-MN has germline predisposition in a considerable proportion. Here, clinical characteristics and germline/somatic variant profiles in T-MN patients were investigated, and the findings were compared with those of previous studies.
Methods
A review of medical records, cytogenetic study, targeted sequencing by next-generation sequencing, and survival analysis were performed on 53 patients with T-MN at a single institution in Korea.
Results
The patients were relatively younger compared to T-MN patients in other studies. Our T-MN patients showed ahigh frequency of complex karyotypes, −5/del(5q), and −7/del(7q), which was similar to the Japanese study group but higher than the Australian study group. The most common primary disease was non-Hodgkin lymphoma, followed by breast cancer. The detailed distributions of primary diseases were different across study groups. Seven patients (13.2%) harbored deleterious presumed/potential germline variants in cancer predisposition genes (CPG) such as BRIP1, CEBPA, DDX41, FANCM, NBN, NF1, and RUNX1. In the somatic variant profile, TP53 was the most frequently mutated gene, which was consistent with the previous studies about T-MN. However, the somatic variant frequency in our study group was lower than in other studies. Adverse factors for overall survival were male sex, older age, history of previous radiotherapy, previous longer cytotoxic therapy, and −5/del(5q).
Conclusion
The findings of our study corroborate important information about T-MN patients. As well as a considerable predisposition to CPG, the clinical characteristics and somatic variant profile showed distinctive patterns. Germline variant testing should be recommended for T-MN patients. If the T-MN patients harbor pathogenic germline variants, the family members for stem cell donation should be screened for carrier status through germline variant testing to avoid donor-derived myeloid neoplasm. For the prediction of the prognosis in T-MN patients, sex, age, past treatment history, and cytogenetic findings can be considered.
ISSN
1479-7364
Language
English
URI
https://hdl.handle.net/10371/192378
DOI
https://doi.org/10.1186/s40246-023-00458-8
Files in This Item:
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share